Literature DB >> 582139

Effects of tocainide on normal and myotonic mammalian skeletal muscle.

R Dengler, R Rüdel.   

Abstract

The effects of the lidocaine derivative 2-amino-2',6'-propionoxylidide hydrochloride (tocainide, W-36095) on the contraction force and on membrane resting and action potentials of rat diaphragm were tested in vitro. In a concentration of 5 x 10(-4) mol/l, tocainide reduced the amplitude of the twitch by about 25% within 15 min. This reduction was reversible on washout of the drug. Tocainide had little effect on the membrane resting potential, but considerably affected the action potential: rate of rise, maximum amplitude and rate of fall were reduced, the duration increased. The conduction velocity of the action potential was reduced by 20%. Experimental myotonia produced in excised diaphragms or in anesthetized whole animals by anthracene-9-carboxylic acid was completely abolished by low doses of tocainide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582139

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Improved therapy of myotonia with the lidocaine derivative tocainide.

Authors:  R Rüdel; R Dengler; K Ricker; A Haass; W Emser
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

Review 2.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

3.  Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

Authors:  K Ricker; A Haass; R Rüdel; R Böhlen; H G Mertens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-03       Impact factor: 10.154

4.  Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Authors:  U Mielke; A Haass; S Sen; W Schmidt
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 5.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

6.  In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.

Authors:  Jean-François Desaphy; Teresa Costanza; Roberta Carbonara; Diana Conte Camerino
Journal:  Neuropharmacology       Date:  2012-09-18       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.